Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Kalaris Therapeutics Inc. (KLRS) had Return on Equity of -21.37% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-11.35M |
|
-- |
|
-- |
|
$12.26M |
|
$-12.26M |
|
$0.91M |
|
$-11.35M |
|
$-11.35M |
|
$-11.35M |
|
$-11.35M |
|
$-11.35M |
|
$-11.35M |
|
$-12.26M |
|
$-12.26M |
|
18.70M |
|
18.70M |
|
$-0.61 |
|
$-0.61 |
|
| Balance Sheet Financials | |
$91.65M |
|
-- |
|
$1.19M |
|
$92.84M |
|
$7.65M |
|
-- |
|
$32.08M |
|
$39.73M |
|
$53.12M |
|
$53.12M |
|
$53.12M |
|
18.70M |
|
| Cash Flow Statement Financials | |
$-19.98M |
|
-- |
|
$107.27M |
|
$1.64M |
|
$88.93M |
|
$87.29M |
|
$0.96M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.98 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.98M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-21.37% |
-21.37% |
|
-12.23% |
|
-21.37% |
|
$2.84 |
|
$-1.07 |
|
$-1.07 |
|